Result for the financial year ended on March 31, 2025 is attached
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 6.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mercury Laboratories reported FY25 revenue from operations of ₹7,510.12 lakhs, marginally down from ₹7,555.90 lakhs in FY24. Net profit after tax fell sharply to ₹314.49 lakhs from ₹565.42 lakhs, a drop of about 44%, with EPS declining to ₹26.21 from ₹47.12. Profit before tax dropped to ₹466.17 lakhs from ₹692.03 lakhs as expenses grew faster than revenue, particularly employee costs which rose to ₹1,684.13 lakhs from ₹1,450.14 lakhs. The board has recommended a final dividend of 35% (₹3.50 per share) and the statutory auditor (Naresh & Co.) issued an unmodified opinion. Cash flow from operations nearly halved to ₹400.11 lakhs, and capital work-in-progress rose sharply to ₹931.88 lakhs indicating ongoing capex.
Sharp decline in profits despite stable revenue suggests margin pressure from rising costs, which may concern shareholders despite the steady dividend payout. The strong capital work-in-progress signals future capacity expansion but also higher depreciation ahead.